Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy
<p>Molecular radiotherapy using <sup>177</sup>Lu-DOTATATE is a most effective treatment for somatostatin receptor–expressing neuroendocrine tumors. Despite its frequent and successful use in the clinic, little or no radiobiologic considerations are made at the ti...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Society of Nuclear Medicine
2019
|
| _version_ | 1826268590561558528 |
|---|---|
| author | O'Neill, E Kersemans, V Allen, P Terry, S Baguna Torres, J Mosley, M Smart, S Lee, B Falzone, N Vallis, K Konijnenberg, M De Jong, M Nonnekens, J Cornelissen, B |
| author_facet | O'Neill, E Kersemans, V Allen, P Terry, S Baguna Torres, J Mosley, M Smart, S Lee, B Falzone, N Vallis, K Konijnenberg, M De Jong, M Nonnekens, J Cornelissen, B |
| author_sort | O'Neill, E |
| collection | OXFORD |
| description | <p>Molecular radiotherapy using <sup>177</sup>Lu-DOTATATE is a most effective treatment for somatostatin receptor–expressing neuroendocrine tumors. Despite its frequent and successful use in the clinic, little or no radiobiologic considerations are made at the time of treatment planning or delivery. On positive uptake on octreotide-based PET/SPECT imaging, treatment is usually administered as a standard dose and number of cycles without adjustment for peptide uptake, dosimetry, or radiobiologic and DNA damage effects in the tumor. Here, we visualized and quantified the extent of DNA damage response after <sup>177</sup>Lu-DOTATATE therapy using SPECT imaging with <sup>111</sup>In-anti-γH2AX-TAT. This work was a proof-of-principle study of this in vivo noninvasive biodosimeter with β-emitting therapeutic radiopharmaceuticals. <strong>Methods:</strong> Six cell lines were exposed to external-beam radiotherapy (EBRT) or <sup>177</sup>Lu-DOTATATE, after which the number of γH2AX foci and the clonogenic survival were measured. Mice bearing CA20948 somatostatin receptor–positive tumor xenografts were treated with <sup>177</sup>Lu-DOTATATE or sham-treated and coinjected with <sup>111</sup>In-anti-γH2AX-TAT, <sup>111</sup>In-IgG-TAT control, or vehicle. <strong>Results:</strong> Clonogenic survival after external-beam radiotherapy was cell-line–specific, indicating varying levels of intrinsic radiosensitivity. Regarding in vitro cell lines treated with <sup>177</sup>Lu-DOTATATE, clonogenic survival decreased and γH2AX foci increased for cells expressing high levels of somatostatin receptor subtype 2. Ex vivo measurements revealed a partial correlation between <sup>177</sup>Lu-DOTATATE uptake and γH2AX focus induction between different regions of CA20948 xenograft tumors, suggesting that different parts of the tumor may react differentially to <sup>177</sup>Lu-DOTATATE irradiation. <strong>Conclusion:</strong> <sup>111</sup>In-anti-γH2AX-TAT allows monitoring of DNA damage after <sup>177</sup>Lu-DOTATATE therapy and reveals heterogeneous damage responses.</p> |
| first_indexed | 2024-03-06T21:12:02Z |
| format | Journal article |
| id | oxford-uuid:3e827d1d-1ecb-41d8-b3c0-56f724065128 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:12:02Z |
| publishDate | 2019 |
| publisher | Society of Nuclear Medicine |
| record_format | dspace |
| spelling | oxford-uuid:3e827d1d-1ecb-41d8-b3c0-56f7240651282022-03-26T14:25:54ZImaging DNA damage repair in vivo following 177Lu-DOTATATE therapyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3e827d1d-1ecb-41d8-b3c0-56f724065128EnglishSymplectic Elements at OxfordSociety of Nuclear Medicine2019O'Neill, EKersemans, VAllen, PTerry, SBaguna Torres, JMosley, MSmart, SLee, BFalzone, NVallis, KKonijnenberg, MDe Jong, MNonnekens, JCornelissen, B<p>Molecular radiotherapy using <sup>177</sup>Lu-DOTATATE is a most effective treatment for somatostatin receptor–expressing neuroendocrine tumors. Despite its frequent and successful use in the clinic, little or no radiobiologic considerations are made at the time of treatment planning or delivery. On positive uptake on octreotide-based PET/SPECT imaging, treatment is usually administered as a standard dose and number of cycles without adjustment for peptide uptake, dosimetry, or radiobiologic and DNA damage effects in the tumor. Here, we visualized and quantified the extent of DNA damage response after <sup>177</sup>Lu-DOTATATE therapy using SPECT imaging with <sup>111</sup>In-anti-γH2AX-TAT. This work was a proof-of-principle study of this in vivo noninvasive biodosimeter with β-emitting therapeutic radiopharmaceuticals. <strong>Methods:</strong> Six cell lines were exposed to external-beam radiotherapy (EBRT) or <sup>177</sup>Lu-DOTATATE, after which the number of γH2AX foci and the clonogenic survival were measured. Mice bearing CA20948 somatostatin receptor–positive tumor xenografts were treated with <sup>177</sup>Lu-DOTATATE or sham-treated and coinjected with <sup>111</sup>In-anti-γH2AX-TAT, <sup>111</sup>In-IgG-TAT control, or vehicle. <strong>Results:</strong> Clonogenic survival after external-beam radiotherapy was cell-line–specific, indicating varying levels of intrinsic radiosensitivity. Regarding in vitro cell lines treated with <sup>177</sup>Lu-DOTATATE, clonogenic survival decreased and γH2AX foci increased for cells expressing high levels of somatostatin receptor subtype 2. Ex vivo measurements revealed a partial correlation between <sup>177</sup>Lu-DOTATATE uptake and γH2AX focus induction between different regions of CA20948 xenograft tumors, suggesting that different parts of the tumor may react differentially to <sup>177</sup>Lu-DOTATATE irradiation. <strong>Conclusion:</strong> <sup>111</sup>In-anti-γH2AX-TAT allows monitoring of DNA damage after <sup>177</sup>Lu-DOTATATE therapy and reveals heterogeneous damage responses.</p> |
| spellingShingle | O'Neill, E Kersemans, V Allen, P Terry, S Baguna Torres, J Mosley, M Smart, S Lee, B Falzone, N Vallis, K Konijnenberg, M De Jong, M Nonnekens, J Cornelissen, B Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy |
| title | Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy |
| title_full | Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy |
| title_fullStr | Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy |
| title_full_unstemmed | Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy |
| title_short | Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy |
| title_sort | imaging dna damage repair in vivo following 177lu dotatate therapy |
| work_keys_str_mv | AT oneille imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT kersemansv imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT allenp imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT terrys imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT bagunatorresj imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT mosleym imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT smarts imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT leeb imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT falzonen imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT vallisk imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT konijnenbergm imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT dejongm imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT nonnekensj imagingdnadamagerepairinvivofollowing177ludotatatetherapy AT cornelissenb imagingdnadamagerepairinvivofollowing177ludotatatetherapy |